

MOLECULAR PHARMACOLOGY

A Publication of the American Society for Pharmacology and Experimental Therapeutics

September 2023

Vol. 104, No. 3

Contents

ARTICLES

- Ⓢ EP4 Receptor Conformation Sensor Suited for Ligand Screening and Imaging of Extracellular Prostaglandins 80
Michael Kurz, Michaela Ulrich, Alwina Bittner, Magdalena Martina Scharf, Jingchen Shao, Imke Wallenstein, Horst Lemoine, Nina Wettschureck, Peter Kolb, and Moritz Bünemann
- Ⓢ Role of Conserved Tyrosine Lid Residues in the Activation of the M₂ Muscarinic Acetylcholine Receptor 92
Vi Pham, Maria Clazina Cornelia Habben Jansen, Geoff Thompson, Laura H. Heitman, Arthur Christopoulos, David M. Thal, and Celine Valant
- Ⓢ Discovery and In Vitro Characterization of BAY 2686013, an Allosteric Small Molecule Antagonist of the Human Pituitary Adenylate Cyclase-Activating Polypeptide Receptor 105
Gernot Langer, John Scott, Christoffer Lind, Christiane Otto, Ulrich Bothe, Alexis Laux-Biehlmann, Jörg Müller, Beau le Roy, Horst Irlbacher, Katrin Nowak-Reppel, Anne Schlüter, Adam J. Davenport, Mark Slack, and Stefan Bäurle
- Chemical, Pharmacological, and Structural Characterization of Novel Acrylamide-Derived Modulators of the GABA_A Receptor 115
Hugo R. Arias, Spencer R. Pierce, Allison L. Germann, Sophia Q. Xu, Marcelo O. Ortells, Seiji Sakamoto, Dina Manetti, Maria Novella Romanelli, Itaru Hamachi, and Gustav Akk

ERRATUM

- Correction to “Sulforaphane Suppresses Polycomb Group Protein Level via a Proteasome-Dependent Mechanism in Skin Cancer Cells” 132

Ⓢ Supplemental material is available online at molpharm.aspetjournals.org.

About the cover: Binding mode proposed for allosteric hPAC1-R inhibitor BAY 2686013. See the article by Langer et al. ([dx.doi.org/10.1124/molpharm.122.000662](https://doi.org/10.1124/molpharm.122.000662)).